Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients get extended access to experimental drug in safety monitoring study

NCT ID NCT03040973

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study provides continued access to the cancer drug capmatinib for patients who were already receiving it in previous Novartis trials and are still benefiting from it. The main goal is to monitor the long-term safety of the treatment in 29 patients with advanced solid tumors. It allows patients to keep receiving their treatment while researchers track any side effects over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WHICH ARE CMET-DEPENDENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Novartis Investigative Site

    Leuven, 3000, Belgium

  • Novartis Investigative Site

    Edmonton, Alberta, T6G 1Z2, Canada

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, 200433, China

  • Novartis Investigative Site

    Kunming, Yunnan, 650106, China

  • Novartis Investigative Site

    Copenhagen, DK-2100, Denmark

  • Novartis Investigative Site

    Dijon, Cote D Or, 21034, France

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    Hanover, 30625, Germany

  • Novartis Investigative Site

    Milan, MI, 20141, Italy

  • Novartis Investigative Site

    Perugia, PG, 06129, Italy

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Madrid, 28040, Spain

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS WHICH ARE CMET-DEPENDENT